pharmaphorum October 6, 2021
Phil Taylor

Exscientia’s artificial intelligence-based drug discovery engine is still largely unproven, but that hasn’t stopped the company raking in funding from investors keen to back its platform.

The final numbers are now in from its recently announced initial public offering on the US Nasdaq, and the numbers are impressive, swelling from an initially forecast $304 million to just over $350 million.

Added to that, Exscientia has just completed a $160 million private placement that ran concurrently with the IPO, backed by SoftBank and the Bill and Melinda Gates Foundation, that swelled its cash reserves by more than half a billion dollars.

The new cash injection adds to $525 million from a fourth-round raise in April, and $100 million in a third-round...

Today's Sponsors

Qure4u
HLTH
ZeOmega

Today's Sponsors

Premier
TripleTree

Today's Sponsor

Transcarent

 
Topics: AI (Artificial Intelligence), Biotechnology, Investments, Pharma / Biotech, Technology, Trends
Report: AI startup funding hits record high of $17.9B in Q3
AI Weekly: Corporate AI labs’ turn toward commercial research highlights need for investment in basic science
WhiteSpace Health Announces $18 Million in New Funding to Build Out AI-driven Revenue Intelligence Platform
“AI 2041” Co-Author Kai-Fu Lee Talks About AI’s Sweeping Future And How He Invests In It
Navina Secures $15 Million in Series A Funding to Continue its Revolution of US Primary Care Using Artificial Intelligence